RT Journal Article
SR Electronic
T1 Humoral Response Dynamics Following Infection with SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.16.20155663
DO 10.1101/2020.07.16.20155663
A1 Grandjean, Louis
A1 Saso, Anja
A1 Torres, Arturo
A1 Lam, Tanya
A1 Hatcher, James
A1 Thistlethwayte, Rosie
A1 Harris, Mark
A1 Best, Timothy
A1 Johnson, Marina
A1 Wagstaffe, Helen
A1 Ralph, Elizabeth
A1 Mai, Annabelle
A1 Colijn, Caroline
A1 Breuer, Judith
A1 Buckland, Matthew
A1 Gilmour, Kimberly
A1 Goldblatt, David
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/07/21/2020.07.16.20155663.abstract
AB Objectives To understand humoral dynamics following SARS-CoV-2 infectionDesign Prospective Cohort StudySetting Great Ormond Street Hospital (Central London Paediatric Hospital)Participants 67 healthcare workers aged >18 years who provided monthly serial serological samples from 29th April 2020 until 30th June 2020.Main outcome measures The change in monthly serial antibody titers to SARS-CoV-2 nucleoprotein (N), spike protein and the receptor binding domain of the spike protein.Results The mean estimated half-life of the nucleoprotein antibody was 52 days (95% CI 42-65). The spike and RBD antibody had significantly longer mean half-lives of 81 days (95% CI 61-111) and 83 days (95% CI 55-137) respectively. An ACE-2 receptor competition assay demonstrated significant correlation between the spike and RBD antibody titers and ACE2 receptor blocking in-vitro. The time to a negative nucleoprotein antibody test for 50% of the seropositive population was predicted to be 195 days (95% CI 163-236).Conclusions After SARS-CoV-2 infection, the predicted half-life of nucleoprotein antibody was 52 days with 50% of seropositives becoming seronegative to this antibody at 195 days. Widely used serological tests that depend on the nucleoprotein antibody will therefore underestimate the true prevalence of infection within a year following the majority of infections.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04380896Funding StatementIn line with UK government policy GOSH NHS Trust made the first diagnostic test available to all staff members in the hospital either as part of the study or outside the study. The GOSH charity provided the funding for follow up testing over the first 6 months of the study. LG declares funding from Wellcome Post-Doctoral Research Fellowship (201470/Z/16/Z). AS declares funding from Wellcome Trust Global Health Clinical Ph.D. Fellowship (220565/Z/20/Z). GOSH NHS Trust hosts a NIHR Funded Biomedical Research Centre which provides infrastructure support permitting translational research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval for the study was granted from the Health Research Authority UKAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be freely available on request